Daiichi Sankyo wins FDA approval for hypertension drug
Jul 27, 2010 (Datamonitor via COMTEX) Daiichi Sankyo, a Japanese pharmaceutical company, has received the FDA’s approval for Tribenzor, a new three-in-one combination product taken once-daily for the treatment of hypertension in patients who are not adequately controlled on any two of the antihypertensive drug classes: angiotensin receptor blockers, calcium channel blockers and diuretics.
According to the company, Tribenzor is not indicated for initial therapy. Approximately 56% of patients taking current blood pressure-lowering therapies do not reach current recommended blood pressure goal of less then 140/90mmHg or less then 130/80mmHg for patients with diabetes, chronic renal disease, or chronic cardiovascular disease. More than two-thirds of patients with high blood pressure will require two or more antihypertensive medications in order to achieve goal blood pressure control.
A fixed-dose combination treatment, Tribenzor, simplifies dosing regimens, reduces pill burden and has the potential to lower co-pays for patients that require three medications to keep blood pressure within recommended levels. Research also shows that the use of fixed-dose antihypertensive combination treatments may improve patient compliance as compared to taking each medication separately, the company said.
Joseph Pieroni, president and CEO of Daiichi Sankyo, said: "Our comprehensive cardiovascular product portfolio provides a variety of treatment options to patients in a number of disease categories including hypertension, heart disease, diabetes and cholesterol.
"Although hypertension is a mature category, the differences among patients will continue to support the need for differentiated products to achieve optimal results. The approval of Tribenzor shows Daiichi Sankyo is committed to optimizing individual patient or redistribution, including by framing or similar means,is expressly prohibited without prior written consent. Datamonitor shallnot be liable for errors or delays in the content, or for any actionstaken in reliance thereon(c) 2010 Datamonitor. All rights reserved
subscribe to comments RSS
Comments are closed